Literature DB >> 1957870

Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis.

B M Sibai1, B Mercer, C Sarinoglu.   

Abstract

A total of 125 women with severe preeclampsia that developed in the second trimester underwent follow-up for an average of 5.4 years. Seventeen women had no further pregnancies and 108 had 169 subsequent pregnancies: 59 (35%) were normotensive and 110 (65%) were complicated by preeclampsia (32% of these developing in the second trimester, 32% at 28 to 36 weeks, and 36% at 37 to 40 weeks). Overall, 21% of subsequent pregnancies were complicated by severe preeclampsia in the second trimester. Forty-four patients (35%) had chronic hypertension, the highest incidence being in those with recurrent severe preeclampsia in the second trimester and the lowest in those with only normotensive subsequent pregnancies (67% vs 4%, p less than 0.0001). Long-term maternal complications included two maternal deaths and two other patients with end-stage renal disease requiring dialysis. We conclude that these women are at increased risk for repeat preeclampsia, particularly in the second trimester, and are at increased risk for chronic hypertension and maternal mortality and morbidity.

Entities:  

Mesh:

Year:  1991        PMID: 1957870     DOI: 10.1016/0002-9378(91)90379-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  42 in total

1.  Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.

Authors:  Ida Martinelli; Piero Ruggenenti; Irene Cetin; Giorgio Pardi; Annalisa Perna; Patrizia Vergani; Barbara Acaia; Fabio Facchinetti; Giovanni Battista La Sala; Maddalena Bozzo; Stefania Rampello; Luca Marozio; Olimpia Diadei; Giulia Gherardi; Sergio Carminati; Giuseppe Remuzzi; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

Review 2.  Hypertension in pregnancy.

Authors:  Maryann Mugo; Gurushankar Govindarajan; L Romayne Kurukulasuriya; James R Sowers; Samy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

3.  Selective serotonin reuptake inhibitor use and risk of gestational hypertension.

Authors:  Sengwee Toh; Allen A Mitchell; Carol Louik; Martha M Werler; Christina D Chambers; Sonia Hernández-Díaz
Journal:  Am J Psychiatry       Date:  2009-01-02       Impact factor: 18.112

Review 4.  Epidemiology of preeclampsia: impact of obesity.

Authors:  Arun Jeyabalan
Journal:  Nutr Rev       Date:  2013-10       Impact factor: 7.110

5.  Fetal and maternal contributions to risk of pre-eclampsia: population based study.

Authors:  R T Lie; S Rasmussen; H Brunborg; H K Gjessing; E Lie-Nielsen; L M Irgens
Journal:  BMJ       Date:  1998-05-02

Review 6.  Liver diseases in pregnancy: diseases unique to pregnancy.

Authors:  Khulood T Ahmed; Ashraf A Almashhrawi; Rubayat N Rahman; Ghassan M Hammoud; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

7.  The two stage model of preeclampsia: variations on the theme.

Authors:  J M Roberts; C A Hubel
Journal:  Placenta       Date:  2008-12-13       Impact factor: 3.481

8.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

9.  Risk for Recurrence of Pre-eclampsia in the Subsequent Pregnancy.

Authors:  Tarakeswari Surapaneni; Vidyavati Patil Bada; C Praveen Kumar Nirmalan
Journal:  J Clin Diagn Res       Date:  2013-12-15

10.  Factors associated with persistent hypertension after puerperium among women with pre-eclampsia/eclampsia in Mulago hospital, Uganda.

Authors:  Emmanuel B Ndayambagye; Miriam Nakalembe; Dan K Kaye
Journal:  BMC Pregnancy Childbirth       Date:  2010-03-12       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.